The clinical, quality of life, and economic consequences of chronic anemia and transfusion support in patients with myelodysplastic syndromes.
about
Comparison of a restrictive versus liberal red cell transfusion policy for patients with myelodysplasia, aplastic anaemia, and other congenital bone marrow failure disordersSafety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndromeThe National Heart, Lung, and Blood Institute Recipient Epidemiology and Donor Evaluation Study (REDS-III): a research program striving to improve blood donor and transfusion recipient outcomesCosts and quality of life in patients with myelodysplastic syndromesMyelodysplastic Syndromes and Iron Chelation TherapyEfficacy and safety of deferasirox in myelodysplastic syndromes.Review of therapeutic options and the management of patients with myelodysplastic syndromes.Toward resolving the unsettled role of iron chelation therapy in myelodysplastic syndromes.An increase in hemoglobin, platelets and white blood cells levels by iron chelation as single treatment in multitransfused patients with myelodysplastic syndromes: clinical evidences and possible biological mechanisms.Arsenic disulfide induced apoptosis and concurrently promoted erythroid differentiation in cytokine-dependent myelodysplastic syndrome-progressed leukemia cell line F-36p with complex karyotype including monosomy 7.Use of n-of-1 (single patient) trials to assess the effect of age of transfused blood on health-related quality of life in transfusion-dependent patients.A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes.Deferasirox chelation therapy in patients with transfusion-dependent MDS: a 'real-world' report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata.Protective effects of deferasirox and N-acetyl-L-cysteine on iron overload-injured bone marrow.Sustained resolution of anemia without any treatment after excessive therapeutic response to human recombinant erythropoietin in three patients with myelodysplastic syndromes.Lenalidomide in International Prognostic Scoring System Low and Intermediate-1 risk myelodysplastic syndromes with del(5q): an Italian phase II trial of health-related quality of life, safety and efficacy.Initial transfusion intensity predicts survival in myelodysplastic syndrome.The evaluation of iron overload through hepcidin level and its related factors in myelodysplastic syndromes.Different effects of granulocyte colony-stimulating factor and erythropoietin on erythropoiesis.
P2860
Q24186615-D74CB025-B18E-4978-A27F-F7152A673D6BQ24632949-502B2996-4A9D-491F-B19D-79EB6C858201Q35251300-66CDF4EC-610C-41D5-995D-3680DFB376B4Q37127532-2A471975-D55F-4052-BEFA-F2F9B7711610Q37677229-8F0800A0-8D39-4ACC-80CE-FB97D00BC599Q38082464-5BCED764-94AF-4A3C-80F5-0EC483128710Q38095121-E25C35B7-54C6-4132-A908-E6A86378F52FQ38196963-0A783671-ADA8-40DC-BB0D-D54AA26C4D22Q38368123-B71A817F-BEA8-4ABB-9B00-3B07924A1A3CQ39017214-0F7EB95C-AD96-4650-8978-D070FAE27786Q40933609-72E485A0-36DE-4698-B5D1-0103100F2FF1Q41186581-4F786C32-A0F4-4D56-A74B-ED535BFA4DBBQ41237697-50EF8CCB-E683-4322-A84D-F9D671AE466EQ42664574-F3661107-7727-4C41-A388-AEC7E1CE6DB7Q45808939-3A51D85E-2781-4CCA-9A13-D4518774D92AQ48293715-AE2C7304-F159-4CFB-906C-003C4AC19F1FQ50481343-AEDEB387-2939-4395-BBAD-67AEAF72BD16Q53113161-9A15C731-9C5E-4010-A218-5E19B307D11DQ55010398-908DDF76-7C0C-47EB-812B-E7C39E67FCDA
P2860
The clinical, quality of life, and economic consequences of chronic anemia and transfusion support in patients with myelodysplastic syndromes.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
The clinical, quality of life, ...... ith myelodysplastic syndromes.
@en
The clinical, quality of life, ...... ith myelodysplastic syndromes.
@nl
type
label
The clinical, quality of life, ...... ith myelodysplastic syndromes.
@en
The clinical, quality of life, ...... ith myelodysplastic syndromes.
@nl
prefLabel
The clinical, quality of life, ...... ith myelodysplastic syndromes.
@en
The clinical, quality of life, ...... ith myelodysplastic syndromes.
@nl
P50
P1433
P1476
The clinical, quality of life, ...... ith myelodysplastic syndromes.
@en
P2093
Kristina Hölig
P304
P356
10.1016/J.LEUKRES.2012.01.006
P577
2012-02-01T00:00:00Z